Pharsight

Drugs that contain Sofosbuvir; Velpatasvir; Voxilaprevir

1. Vosevi patents expiration

VOSEVI's oppositions filed in EPO
VOSEVI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(5 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(6 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(6 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(5 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(5 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(5 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(7 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(9 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(10 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(13 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(13 years from now)

US11338007

(Pediatric)

GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

NCE-1 date: 2021-07-18

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...

Dosage: TABLET;ORAL

More Information on Dosage

VOSEVI family patents

Family Patents